Stryker Corporation (syk)
SYK — Company Overview
Stryker Corporation (SYK) is a large-cap company in the Healthcare sector, operating in Medical Devices.
| Ticker | SYK |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NYQ |
| Market cap | $129.43B |
| Last price | $337.43 |
| Size category | Large Cap |
SYK — Business Description
Stryker Corporation (SYK) operates in Medical Devices within the broader Healthcare market. Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products…
Official website: https://www.stryker.com.
SYK — Investment Thesis
The investment thesis for Stryker Corporation (SYK) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 9.4% year-over-year (public data).
- Trailing P/E of 34.97× sits in a moderate band relative to high-growth peers.
- Forward P/E (20.13×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 1.0% adds an income component to total return.
- Equity market capitalization is approximately $129.43B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
SYK — Financial Health
Financial health for Stryker Corporation (SYK) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin near 14.4% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $4.11B supports balance-sheet flexibility.
| Trailing P/E | 34.97× |
| Forward P/E | 20.13× |
| Price / Sales | 5.01× |
| Price / Book | 5.63× |
| Gross margin | 65.6% |
| Operating margin | 27.0% |
| Profit margin | 14.4% |
| Return on equity | 16.5% |
| Debt / Equity | 64.39 |
| Free cash flow | $4.11B |
SYK — Growth Outlook
Growth outlook for Stryker Corporation (SYK) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 9.4% suggests steady but measured expansion.
- Earnings growth of 44.1% year-over-year supports improving profitability.
- Price is 15.0% below the 52-week high.
- Shares trade 20.1% above the 52-week low — limited rebound so far.
SYK — Competitive Position
Stryker Corporation (SYK) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $129.43B places SYK among large-cap peers.
- Gross margin near 65.6% may reflect pricing power or favorable mix.
SYK — Strengths
Strengths for Stryker Corporation (SYK) inferred from public financial metrics:
- Revenue growth of 9.4% year-over-year.
- Earnings growth of 44.1% year-over-year.
- Return on equity near 16.5% — efficient use of shareholder capital.
- Gross margin of 65.6% supports competitive unit economics.
- Positive free cash flow ($4.11B).
- Moderate leverage (debt/equity 64.39).
SYK — Weaknesses
Weaknesses and pressure points for Stryker Corporation (SYK) based on available data:
Insufficient public data to assess this factor.
SYK — Opportunities
- Sustained revenue growth (9.4%) could support multiple expansion if margins hold.
- Trading 20.1% above the 52-week low — potential recovery if fundamentals stabilize.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
SYK — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
SYK — Summary
Stryker Corporation (SYK) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $337.43 with market cap $129.43B. Trailing P/E 34.97×. Revenue grew 9.4% year-over-year per public data. Notable strengths include revenue growth of 9.4% year-over-year. Detailed estimates, ownership, and news for Stryker Corporation remain locked in Vest Terminal for subscribers.
Stryker Corporation FAQ
What does Stryker Corporation (SYK) do?
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety…
What is SYK's P/E ratio?
Stryker Corporation has a trailing P/E of 34.97× based on publicly available market data.
Does SYK pay a dividend?
Indicated dividend yield: 1.0%. Confirm ex-dates and payout history in Vest Terminal.
What sector is SYK in?
Stryker Corporation is classified in Healthcare (Medical Devices) on NYQ.
What is SYK's market capitalization?
Approximate market cap: $129.43B.
What are the main risks for SYK?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of SYK?
Potential positives include revenue growth of 9.4% year-over-year, earnings growth of 44.1% year-over-year.
Where can I get analyst estimates for SYK?
Consensus estimates, price targets, and detailed analyst data for Stryker Corporation are available to Professional subscribers in Vest Terminal — not on this public summary page.